DATOM Record · DTM-2026-0703-2E
GLP-1 weight-loss drugs cause you to lose muscle while you lose weight.
DATOM looked at 102 studies that directly tested this claim. Of those, 77 (75%) support the idea that GLP-1 weight-loss drugs cause you to lose muscle while you lose weight; 25 (25%) point the other way. So as the evidence stands today, most of the clear findings back the claim — that is what the “Supported” verdict below means. But the Grade D beside it matters just as much: the evidence base is limited, so this is the current direction of the evidence, not a settled, high-certainty result.
Exact claim checked GLP-1 receptor agonist therapy at clinically approved doses reduces skeletal muscle mass during weight loss in overweight and obese adults, as measured by lean body mass or appendicular skeletal muscle mass over a treatment period of 12 to 68 weeks.
Domainclinical medicine
Supported means most of the clear findings point this way. It does not mean the claim is proven beyond doubt, and it does not mean every study agrees. It means the evidence, as it stands today, backs it.
Evidence Grade
Grade D · limited evidence base
Is this medical advice? No. This looks at whether current evidence supports one specific claim. It does not cover safety, dosing, or side effects, and it is not a recommendation to use or avoid any medication. Talk to a doctor before making a decision about your health.
What the evidence looks like
Of the 102 studies that directly tested this claim:
The studies · a sample of the evidence base, the three that weigh most first
- ContradictsOpportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy.. Satya Dash, 2024, n/a. doi.org/10.1111/dom.15829
- ContradictsBimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. S. Heymsfield et al., 2026, n/a. doi.org/10.1038/s41591-026-04204-0
- ContradictsDionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis. Yanying Wang et al., 2025, n/a. doi.org/10.1186/s13098-025-01877-4
Show the other 11
- ContradictsThe impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.. Konstantinos Stefanakis et al., 2024, n/a. doi.org/10.1016/j.metabol.2024.156057
- ContradictsOral Nutritional Supplements and Body Composition Outcomes Among GLP-1 Receptor Agonist Users: Real-World Evidence.. Kurt Hong et al., 2026, n/a. doi.org/10.2147/DMSO.S574765
- ContradictsWeighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity?. Konstantinos Prokopidis et al., 2025, n/a. doi.org/10.1016/j.jnha.2025.100652
- ConditionalAdvantage of Semaglutide: Comprehensive Analysis of Metabolic Impact of Semaglutide‐Treated and Pair‐Fed Rats. Suyeun Byun et al., 2025, n/a. doi.org/10.1002/cph4.70083
- ConditionalEffects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.. Valeria Gutierrez de Piñeres et al., 2026, n/a. doi.org/10.1016/j.diabres.2026.113113
- ConditionalPreserving the Metabolic Engine: Muscle as the Therapeutic Target for Cardiovascular Prevention in Obesity Pharmacotherapy.. Fabian Sanchis-Gomar et al., 2025, n/a. doi.org/10.1007/s11886-025-02334-4
- ConditionalMoving beyond the scale: musculoskeletal risks, evidence gaps and emerging combination strategies to optimize the quality of weight loss pharmacotherapy in older adults. Kieran F. Reid et al., 2025, n/a. doi.org/10.3389/fragi.2025.1640030
- SupportsSEMAGLUTIDE AND BODY COMPOSITION: A NARRATIVE REVIEW OF ITS EFFECTS ON LEAN MASS AND STRATEGIES FOR PRESERVATION. Anna Tomasiewicz et al., 2025, n/a. doi.org/10.31435/ijitss.3(47).2025.4067
- SupportsThe Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition.. Lampros Chrysavgis et al., 2025, n/a. doi.org/10.3390/ijms262412130
- SupportsWeight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. J. Wilding et al., 2022, n/a. doi.org/10.1111/dom.14725
- SupportsMuscle health in the modern era of incretin-based therapies.. Giuseppe De Girolamo et al., 2026, n/a. doi.org/10.1111/eci.70155
Every study links to the original. The three highlighted weigh most. Some studies in the list bear on the claim only under certain conditions (tagged Conditional) and sit outside the 102 that directly tested it, which is why the sample and the bar above count different things. The complete evidence base is in the full Confidence Report.
• Watched. The verdict and grade update as new studies on this claim are found. · How DATOM checks a claim
DATOM is the public record of scientific claims, checked independently, updated as evidence changes.